Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$169.6MCash on Hand
26.2mo Cash Runway
Follow CTY by emailGet an email when CTY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CTY, unsubscribe in one click. Privacy
📣 What CTY Says Is Next
by year-end · CITY-RBP4: “With two programs now in the clinic and a third program expected to enter the clinic through an investigator-initiated trial by year-end, we continue to leverage our City Platform to develop RNAi therapeutics designed to deliver meaningful and durable benefits for patients in need.”
Company press release, Nov 10, 2026 · SEC filing
mid-2027 · CITY-RBP4: “City expects to report initial data from the Phase 1 trial in mid-2027.”
Company press release, Nov 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Clinical trial Announced the first participant dosed in a Phase 1 trial of CITY-RBP4, an RNAi candidate for Stargardt disease. Initial data from the trial are expected in mid-2027. Form 8-K · SEC filing · Press release
Oct 19, 2026 ·
Shareholder vote City Therapeutics filed its amended and restated certificate of incorporation with Delaware on October 19, 2026, authorizing 500,000,000 common shares and 10,000,000 undesignated preferred shares, and eliminating stockholder written consent and special meetings. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Feb 2028 · Phase 1 · Recruiting · A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants Registry primary completion date, not a results date
Mar 2028 · Phase 1 · Recruiting · A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, and Adults With a History of… Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CTY holds $169.6M in cash and short-term investments and burns about $19.4M/quarter from operations,
an estimated runway of 26.2 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CTY and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.